



28th December, 2023

The Manager,
Listing Compliance Department,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400051

Corporate Office :
406, Silver Oaks Comm. Complex,
Opp. Arun Society, Paldi,
Ahmedabad-380 007. Gujarat, India.
Phone : 079-26584655
Fax : 079-26588054
CIN No. : L24231GJ2004PLC043861
E-mail : info@sakarhealthcare.com
Web : www.sakarhealthcare.com

Symbol: SAKAR

Dear Sir,

Sub: Outcome of Board Meeting

Ref.: NSE 'In principle' approval granted vide Ref. no. Ref: NSE/LIST/38623 dated 20th December, 2023 under Regulation 28(1) of SEBI (ICDR) Regulations, 2018

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 & in furtherance to earlier communication dated 21st November, 2023, we hereby inform you that the Meeting of Board of Directors of the Company ("Board") was held today i.e. 28th December, 2023, wherein, the Board approved the following:

1. Allotment of Equity Shares.

Allotted 4,00,000 Equity Shares of Rs. 10/- each at a price of Rs. 384/- per Equity Share including premium of Rs. 374/- per Equity Share to Non-Promoter person as mentioned in Annexure A, on Preferential basis in accordance with the provisions of Companies Act, 2013 and SEBI (ICDR) Regulations, 2018 for Preferential Issues; and

2. Allotment of Warrants (convertible into equal number of Equity Shares).

Allotted 5,00,000 Warrants (convertible into equal number of Equity Shares) of Rs. 10/- each (hereinafter referred as 'Convertible Warrants') at a price of Rs. 384/- per Warrant including premium of Rs. 374/- per Warrant to Promoters and Non-Promoters as mentioned in Annexure A, on Preferential basis in accordance with the provisions of Companies Act, 2013 and SEBI (ICDR) Regulations, 2018 for Preferential Issues.

In accordance with Regulation 30 of Listing Regulations, the necessary disclosures are enclosed herewith as Annexure A.

We will approach you in due course of time for Listing Application in terms of SEBI Listing Regulations.

The Board Meeting commenced at 11:00 a.m. and concluded at 11:30 a.m.

Kindly take same on your record.

Thanking you,

Yours faithfully,

FOR SAKAR HEALTHCARE LIMITED

TS
BHARAT SONI
COMPANY SECRETARY
& COMPLIANCE OFFICER




ANNEXURE A
DETAILS OF PREFERENTIAL ISSUE/ALLOTMENT

Sr. No.	Particulars of disclosure	Equity Shares	Convertible Warrants																																																					
1.	Types of securities issued	Equity shares having face value of ₹10/- per equity share ("Equity Shares").	Warrants (Convertible into equal number of Equity Shares) having face value ₹10/- each																																																					
2.	Type of issuance/allotment	Preferential Issue - Allotment	Preferential Issue - Allotment																																																					
3.	Total number of securities issued	4,00,000 Equity Shares of face value ₹10/- each, at an issue price of ₹384/- per share	5,00,000 Warrants having face value of ₹10/- each, at an issue price of ₹384/- per warrant which will be convertible into equal number of equity shares within a period of 18 months from the date of allotment. Note:- - The tenure of Warrants will be 18 months. - 25% of the total consideration is paid at the time of issuance/allotment of the warrants and the remaining 75% of the total consideration shall be paid upon the exercise/ conversion of each warrant.																																																					
4.	Details to be furnished in case of preferential issue																																																							
	a. Name of the investors	Non Promoters: 1. Hi-Tech Chemicals Limited	Promoters: 1.Sanjay Shah 2. Aarsh Shah Non Promoters: 3. Hemant Gadodia 4. Prakash Diwan 5. Sunil Kabra 6. Hi-Tech Chemicals Limited																																																					
	b. Post allotment of securities outcome of the subscription, issue price /allotted price (in case of convertibles), number of investors	Outcome of allotment: <table><tr><th rowspan="2">Investor</th><th colspan="2">Pre-Issue equity shareholding</th><th colspan="2">Post-issue equity shareholding*</th></tr><tr><th>No.</th><th>%</th><th>No.</th><th>%</th></tr><tr><td>Hi-Tech Chemicals Limited</td><td>-</td><td>-</td><td>4,00,000</td><td>1.80</td></tr></table> <p>*Assuming post issuance of equity shares on fully diluted basis and all the warrants are exercised. *Post allotment of Equity Shares and conversion of warrants into Equity, the total Shareholding would be 6,00,000 Equity Shares representing 2.70% of post issue capital</p> <p>Issue Price: Equity Shares allotted to the aforementioned allottee at a price of Rs. 384/- each.</p>	Investor	Pre-Issue equity shareholding		Post-issue equity shareholding*		No.	%	No.	%	Hi-Tech Chemicals Limited	-	-	4,00,000	1.80	Outcome of allotment: <table><tr><th rowspan="2">Investor</th><th colspan="2">Pre-Issue equity shareholding</th><th colspan="2">Post-issue Equity Shareholding*</th></tr><tr><th>No.</th><th>%</th><th>No.</th><th>%</th></tr><tr><td>Sanjay Shah</td><td>99,08,543</td><td>46.41</td><td>1,00,08,543</td><td>44.98%</td></tr><tr><td>Aarsh Shah</td><td>13,07,500</td><td>6.12</td><td>14,07,500</td><td>6.33%</td></tr><tr><td>Hemant Gadodia</td><td>NIL</td><td>NIL</td><td>34,000</td><td>0.15%</td></tr><tr><td>Prakash Diwan</td><td>20,000</td><td>0.09%</td><td>53,000</td><td>0.24%</td></tr><tr><td>Sunil Kabra</td><td>NIL</td><td>NIL</td><td>33,000</td><td>0.15%</td></tr><tr><td>Hi-Tech Chemicals Limited⁵</td><td>NIL</td><td>NIL</td><td>2,00,000</td><td>0.90%</td></tr></table>	Investor	Pre-Issue equity shareholding		Post-issue Equity Shareholding*		No.	%	No.	%	Sanjay Shah	99,08,543	46.41	1,00,08,543	44.98%	Aarsh Shah	13,07,500	6.12	14,07,500	6.33%	Hemant Gadodia	NIL	NIL	34,000	0.15%	Prakash Diwan	20,000	0.09%	53,000	0.24%	Sunil Kabra	NIL	NIL	33,000	0.15%	Hi-Tech Chemicals Limited ⁵	NIL	NIL	2,00,000	0.90%
Investor	Pre-Issue equity shareholding			Post-issue equity shareholding*																																																				
	No.	%	No.	%																																																				
Hi-Tech Chemicals Limited	-	-	4,00,000	1.80																																																				
Investor	Pre-Issue equity shareholding		Post-issue Equity Shareholding*																																																					
	No.	%	No.	%																																																				
Sanjay Shah	99,08,543	46.41	1,00,08,543	44.98%																																																				
Aarsh Shah	13,07,500	6.12	14,07,500	6.33%																																																				
Hemant Gadodia	NIL	NIL	34,000	0.15%																																																				
Prakash Diwan	20,000	0.09%	53,000	0.24%																																																				
Sunil Kabra	NIL	NIL	33,000	0.15%																																																				
Hi-Tech Chemicals Limited ⁵	NIL	NIL	2,00,000	0.90%																																																				



Sr. No.	Particulars of disclosure	Equity Shares	Convertible Warrants
		Number of Investors: Allotment is made to one investor only as already disclosed	<p>* Assuming post issuance of equity shares on fully diluted basis and all the warrants are exercised.</p> <p>5 Post allotment of Equity Shares and conversion of warrants into Equity, the total Shareholding would be 6,00,000 Equity Shares representing 2.70% of post issue capital</p> <p>Issue Price: Warrants (convertible into equal number of equity shares) allotted to the aforementioned allottees at a price of Rs. 384/- each.</p> <p>Number of Investors: Allotment is made to six investors as already disclosed</p>
	In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument	Not Applicable	<p>Each warrant shall be convertible into 1 (one) equity shares within a period of 18 (eighteen) months from the date of allotment in one or more tranches, as the case may be and on such other terms and conditions as applicable upon exercise of option of conversion by the warrant holder.</p> <p>25% of the total consideration is paid at the time of issuance of the warrants and the remaining 75% of the total consideration shall be paid upon the exercise/ conversion of each warrant within a period of 18 months of allotment of warrants.</p> <p>The warrants conversion can be exercised at any time within a period of 18 months from the date of allotment, in one or more tranches, as the case may be and on such other terms and conditions as applicable.</p>
5.	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not Applicable	Not Applicable
6.	Lock in	The Equity Shares is subject to 'lock-in' as prescribed under the applicable provisions of the SEBI ICDR Regulations.	The Warrants and the Equity Shares upon conversion shall be subject to 'lock-in' as prescribed under the applicable provisions of the SEBI ICDR Regulations.

For SAKAR HEALTHCARE LIMITED


BHARAT SONI
COMPANY SECRETARY &
COMPLIANCE OFFICER

